42590-00-1

Basic information

• Product Name: Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate
• Synonyms: Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate;Methyl 4-hydroxy-3-methoxy-5-nitrobenzoate 95+%;2-Hydroxy-3-methoxy-5-(methoxycarbonyl)nitrobenzene;2-Hydroxy-3-methoxy-5-(methoxycarbonyl)nitrobenzene, 2-Methoxy-4-(methoxycarbonyl)-6-nitrophenol, 2-Hydroxy-5-(methoxycarbonyl)-3-nitroanisole, Methyl 4-hydroxy-5-nitro-m-anisate;Methyl 4-hydroxy-3-methoxy-5-nitrobenzoate;4-hydroxy-3-methoxy-5-nitrobenzoic acid methyl ester;4-hydroxy-3-methoxy-5-nitro-benzoic acid methyl ester
• CAS NO: 42590-00-1
• Molecular Formula: C₉H₉NO₆
• Molecular Weight: 227
• Mol File: 42590-00-1.mol
• Article Data: 13

Chemical Properties

• Melting Point: 154-155 °C
• Boiling Point: 354.1°C at 760 mmHg
• Flash Point: 167.9°C
• Appearance: /
• Density: 1.405g/cm³
• Vapor Pressure: 1.68E-05mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.36±0.38(Predicted)
• CAS DataBase Reference: Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate(42590-00-1)
• EPA Substance Registry System: Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate(42590-00-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 42590-00-1(Hazardous Substances Data)

Usage

General Description

Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate is a chemical compound with the molecular formula C10H9NO6. It is known for its yellow crystalline appearance and is commonly used in the pharmaceutical industry for the synthesis of various medications. Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate is also used as an intermediate in the production of certain dyes and pigments. Methyl 4-hydroxy-3-methoxy-5-nitrobenzenecarboxylate is considered to be a potentially hazardous chemical and should be handled with care.

InChI:InChI=1/C9H9NO6/c1-15-7-4-5(9(12)16-2)3-6(8(7)11)10(13)14/h3-4,11H,1-2H3

Upstream product

• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 60-29-7 diethyl ether 
• 7697-37-2 nitric acid 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 67-56-1 methanol 
• 15785-54-3 5-nitrovanillic acid 

Downstream Products

• 63603-09-8 methyl 4-chloro-3-methoxy-5-nitrobenzoate 
• 92643-72-6 3-amino-4-hydroxy-5-methoxybenzoic acid methyl ester 
• 84211-27-8 3-amino-4,5-dihydroxybenzoic acid 
• 1391712-50-7 5-[3-(2,5-dichloro-4,6-dimethyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-2-hydroxy-3-methoxy-1-nitrobenzene 

Relevant articles and documents

Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics

Despite extensive research on small molecule thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug. We have undertaken major efforts to identify neutral, non-prodrug inhibitors. Using a holistic analysis of all available internal data, we were able to build computational models and apply these for the selection of a lead series with the highest possibility of achieving oral bioavailability. In our design, we relied on protein structure knowledge to address potency and identified a small window of favorable physicochemical properties to balance absorption and metabolic stability. Protein structure information on the pregnane X receptor helped in overcoming a persistent cytochrome P450 3A4 induction problem. The selected compound series was optimized to a highly potent, neutral, non-prodrug thrombin inhibitor by designing, synthesizing, and testing derivatives. The resulting optimized compound, BAY1217224, has reached first clinical trials, which have confirmed the desired pharmacokinetic properties.

Benzimidazolecarboxylic acid fragment in GSK484 and preparation method of benzimidazolecarboxylic acid fragment

The invention discloses a preparation method of a benzimidazolecarboxylic acid fragment in GSK484, and belongs to the field of chemical and pharmaceutical intermediates, wherein the benzimidazolecarboxylic acid fragment has a chemical name of 1-methyl-2-(

NEW HETEROCYCLIC COMPOUNDS

The invention provides new heterocyclic compounds having the general formula (IA) wherein A, L, X, Y, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.